Trading of Cue Biopharma was halted at 09:38 AM ET due to "LULD Pause" and resumed at 09:48 AM ET. NASDAQ:CUE Cue Biopharma (CUE) Stock Price, News & Analysis $4.55 -0.21 (-4.43%) As of 09:53 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC FilingsShort Interest About Cue Biopharma Stock (NASDAQ:CUE) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Cue Biopharma alerts:Sign Up Key Stats Today's Range$3.85▼$4.6250-Day Range$2.83▼$37.8452-Week Range$2.83▼$45.50Volume542,749 shsAverage Volume406,816 shsMarket Capitalization$33.03 millionP/E RatioN/ADividend YieldN/APrice Target$83.00Consensus RatingHold Company Overview Cue Biopharma, Inc. is a biotechnology company developing biologic medicines designed to selectively engage and modulate T cells. Its Immuno-STAT platform is intended to direct immune activity toward disease-specific targets, with potential applications in cancer and autoimmune disorders.The company’s research has included cancer candidates such as CUE-101, designed to target HPV16-positive cancers, and CUE-102, developed to target cancers expressing the WT1 protein. Cue Biopharma has also pursued programs intended to influence immune responses in autoimmune disease.Based in Cambridge, Massachusetts, Cue Biopharma works in the biotechnology sector. Its approach focuses on engineering biologics to shape the body’s T-cell response rather than broadly activating or suppressing the immune system.AI Generated. May Contain Errors. Read More Cue Biopharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks49th Percentile Overall ScoreCUE MarketRank™: 2.458230621745 of 5 starsCue Biopharma scored higher than 49% of companies evaluated by MarketBeat, and ranked 935th out of 1,704 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingHold Consensus RatingCue Biopharma has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and 1 sell rating.Upside PotentialCue Biopharma has a consensus price target of $83.00, representing about 1,643.7% upside from its current price of $4.76.Amount of Analyst CoverageCue Biopharma has only been the subject of 3 research reports in the past 90 days.Read more about Cue Biopharma's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Cue Biopharma are expected to grow in the coming year, from ($21.79) to ($8.70) per share.Price to Book Value per Share RatioCue Biopharma has a P/B Ratio of 0.47. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted13.90% of the float of Cue Biopharma has been sold short.Short Interest Ratio / Days to CoverCue Biopharma has a short interest ratio ("days to cover") of 7.57.Change versus previous monthShort interest in Cue Biopharma has recently increased by 8.86%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCue Biopharma does not currently pay a dividend.Dividend GrowthCue Biopharma does not have a long track record of dividend growth. News and Social Media1.8 / 5News Sentiment-0.10 News SentimentCue Biopharma has a news sentiment score of -0.10. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.38 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Cue Biopharma this week, compared to 3 articles on an average week.MarketBeat Follows4 people have added Cue Biopharma to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Cue Biopharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $389,260.00 in company stock.Percentage Held by Insiders14.56% of the stock of Cue Biopharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions35.04% of the stock of Cue Biopharma is held by institutions.Read more about Cue Biopharma's insider trading history. Receive CUE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cue Biopharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CUE Stock News HeadlinesCue Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 17 at 1:24 PM | marketscreener.comMCue Biopharma Q3 2026: What's Behind the Wider-Than-Expected LossNovember 16 at 5:22 PM | 247wallst.comToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one lesser known company. With plans filed for 1,000,000 new satellites, that licensing fee could scale dramatically. Analyst Dylan says the stock could move by December 8th.November 19 at 1:00 AM | Behind the Markets (Ad)Cue Biopharma Reports Third Quarter 2026 Financial Results and Recent Business HighlightsNovember 16 at 5:00 PM | globenewswire.comCue Biopharma Reports Positive CUE-221 Phase 2 CSU Results and Initiates First-in-Human Dosing of CUE-401November 16 at 4:51 PM | quiverquant.comQCue Biopharma (CUE) Set to Release Earnings on WednesdayNovember 10, 2026 | americanbankingnews.comCue Biopharma (CUE) Reports Hives Drug Results. Can Longer Relief Set it Apart?September 26, 2026 | finance.yahoo.comCue Biopharma: Initiating 'Buy' Based On CUE-221 Trial Win CSU With Novel Dual MOASeptember 21, 2026 | seekingalpha.comSee More Headlines CUE Stock Analysis - Frequently Asked Questions How have CUE shares performed this year? Cue Biopharma's stock was trading at $274.86 at the start of the year. Since then, CUE stock has decreased by 98.3% and is now trading at $4.76. How were Cue Biopharma's earnings last quarter? Cue Biopharma, Inc. (NASDAQ:CUE) released its earnings results on Monday, November, 16th. The company reported ($4.74) earnings per share for the quarter, missing analysts' consensus estimates of ($2.24) by $2.50. The company earned $132 thousand during the quarter, compared to analysts' expectations of $1.03 million. Cue Biopharma had a negative net margin of 579.95% and a negative trailing twelve-month return on equity of 820.77%. When did Cue Biopharma's stock split? Shares of Cue Biopharma reverse split on Thursday, April 23rd 2026.The 1-30 reverse split was announced on Wednesday, April 22nd 2026. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, April 22nd 2026. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. When did Cue Biopharma IPO? Cue Biopharma (CUE) raised $62 million in an initial public offering (IPO) on Tuesday, January 2nd 2018. The company issued 8,820,710 shares at a price of $6.00-$8.00 per share. Who are Cue Biopharma's major shareholders? Cue Biopharma's top institutional investors include Nantahala Capital Management LLC (1.32%), State Street Corp (0.44%), Texas Capital Bank Wealth Management Services Inc (0.38%) and Robertson Stephens Wealth Management LLC (0.15%). Insiders that own company stock include Shao-Lee Lin, Sumita Ray, Michael Vincent Meluzio and Daniel R Passeri. View institutional ownership trends. How do I buy shares of Cue Biopharma? Shares of CUE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Cue Biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cue Biopharma investors own include NVIDIA (NVDA), Tesla (TSLA), Palantir Technologies (PLTR), Advanced Micro Devices (AMD), Atomera (ATOM), Taiwan Semiconductor Manufacturing (TSM) and Micron Technology (MU). Company Calendar Last Earnings11/16/2026Today11/19/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (2d) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 As of 2 days ago, CUE's financial health entered the Red zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:CUE CIK1645460 Webwww.cuebiopharma.com Phone(617) 949-2680FaxN/AEmployees29Year Founded2015Price Target and Rating Average Price Target for Cue Biopharma$83.00 High Price Target$83.00 Low Price Target$83.00 Potential Upside/Downside+1,773.6%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($29.66) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$26.60 million Net Margins-579.95% Pretax Margin-434.50% Return on Equity-820.77% Return on Assets-398.14% Debt Debt-to-Equity RatioN/A Current Ratio1.25 Quick Ratio1.25 Sales & Book Value Annual Sales$27.47 million Price / Sales1.17 Cash FlowN/A Price / Cash FlowN/A Book Value$10.08 per share Price / Book0.44Miscellaneous Outstanding Shares7,260,000Free Float6,206,000Market Cap$32.16 million OptionableNo Data Beta2.79 Social Links 7 Blue-Chip Stocks to Add To Your Forever PortfolioA strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership. This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.Get This Free Report This page (NASDAQ:CUE) was last updated on 11/19/2026 by MarketBeat.com Staff. From Our PartnersChase, Wells Fargo and Capital One all showed errors on Nov. 16On November 16, customers of Chase, Bank of America, Wells Fargo, Capital One and Zelle reported errors when t...Cedar Gold Group | SponsoredYour $7 scanner is waitingThe Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which sto...Profits Run | SponsoredPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It...OilPrice | SponsoredThe Democrats can’t stop thisPorter Stansberry believes President Trump has begun a full dollar reset through executive order 14241, bypass...Porter & Company | SponsoredTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredYour father's savings lost half their value after 1971.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredA Bill Would Reprice America's Gold at Market ValueThe US government still values its gold at $42 an ounce, a price Congress set in 1973. Gold trades above $4,00...Concord Gold Capital | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cue Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cue Biopharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.